Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dWosCfbwoceObjcpVzqr

October 12, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • FDA could speed approval process for certain drugs
    Treatments whose public health benefits outweigh their risks, including drugs for drug-resistant bacteria, infectious diseases and obesity, could be fast-tracked for approval under plans being considered by the FDA. Commissioner Dr. Margaret Hamburg said such drugs could be labeled for "special medical use" after faster, smaller clinical trials to get them to the people who need them most. "A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Allan Coukell of Pew Health Group, who has been involved in the FDA talks. Bloomberg Businessweek (10/11) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
 
  • Lilly chief: TPP must set standard for biologic data exclusivity
    Not all participants in the Trans-Pacific Partnership trade negotiations share the U.S.' commitment to 12 years of data exclusivity for biologics, and that's why it's necessary that the eventual agreement set a standard that will encourage biopharmaceutical investment and innovation, writes Eli Lilly and Co. chairman, president and CEO John C. Lechleiter. "Furthermore, TPP will set the standard for countries such as China that are not part of the trade agreement, so America must stand firm: we cannot sacrifice the fundamental incentives that drive biomedical R&D investments," he writes. Forbes (10/10) LinkedInFacebookTwitterEmail this Story
  • Vaccine shows promise in wiping out HPV-infected cells in women
    Inovio Pharmaceuticals' vaccine VGX-3100 shows promise in helping women with human papillomavirus infections and are at risk for cervical cancer, according to a study in Science Translational Medicine. Researchers found that the vaccine, which contains DNA pieces, helps women develop an immune system that could attack and wipe out HPV-infected cells. The study also showed the vaccine's potential in hindering precancerous cells from becoming cancerous. MyHealthNewsDaily.com (10/10) LinkedInFacebookTwitterEmail this Story
  • Genome interpreter keeps data local for better privacy
    The Knome knoSYS 100 can interpret one sequenced genome per day based on current knowledge and keeps the analysis local, appealing to patients and clinicians who worry about keeping personal genomic data private. The device can help bridge the gap between the lab and the clinic by helping clinicians understand sequencing data, Knome CEO Martin Tolar says. Nature (10/9) LinkedInFacebookTwitterEmail this Story
Online Biotech Grad Programs from Johns Hopkins
Become a leader in biotechnology with a graduate program from Johns Hopkins AAP. We offer 8 flexible online graduate degrees and certificates ranging from Biotech to Regulatory Science. Gain the expertise necessary to excel in and beyond the lab at a world-renowned university. Learn more.
ADVERTISEMENT
Advertisement
  Company & Financial News 
  • Benitec gains hepatitis C drug with Tacere buyout
    Benitec Biopharma agreed to buy Tacere Therapeutics, whose hepatitis C drug candidate TT-034 is based on Benitec's gene-silencing technology. The allocation of licensing revenue and $1.5 million in new Benitec shares will depend on when in the drug's development it is licensed. Australian Life Scientist (10/11) LinkedInFacebookTwitterEmail this Story
  • Kythera obtains $70.4M in IPO to advance double-chin drug
    Kythera Biopharmaceuticals secured around $70.4 million from selling 4.4 million shares in an initial public offering. Almost all proceeds will go toward the Phase III trials of ATX-101, an experimental treatment for double chin. Kythera and partner Bayer Consumer Care plan to file an application in Europe for ATX-101 next year. CNBC/The Associated Press (10/11) LinkedInFacebookTwitterEmail this Story
  • MedGenesis receives grant for experimental Parkinson's drug
    Deutsche Parkinson Vereinigung e.V. awarded MedGenesis Therapeutix a grant to support midstage development of glial-cell-line-derived neurotrophic factor, a potential treatment for Parkinson's disease. "GDNF has the potential to become the first disease-modifying treatment in Parkinson's disease and could significantly change the quality of life of the affected patients," MedGenesis Chairman and CEO Erich Mohr said. Pharmaceutical Business Review Online (10/11) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • Support for biotech labeling law declined sharply, poll shows
    Support for California's Proposition 37 biotech labeling law dropped from 66.9% in late September to 48.3% in early October, according to polling of likely voters from the California Business Roundtable and Pepperdine University. The latest survey, conducted Sunday to Wednesday, had a margin of error of plus or minus 3.4%. Ventura County Star (Calif.) (free registration) (10/11) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • RFS waiver won't improve economy and corn prices, BIO says
    Waiving the Renewable Fuel Standard would harm biotech employers without helping the economy, BIO said in a letter to the EPA. "The petitions, as presented for comment, fail to demonstrate that continued implementation of the RFS would severely harm the economy or the environment of a State, a region, or the United States as a whole during the waiver period," according to the letter. BIO cites two studies showing an RFS waiver won't reverse the economic damage caused by drought. BiofuelsDigest.com (10/10) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Children have never been very good at listening to their elders, but they have never failed to imitate them."
--James Baldwin,
American writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information